Blood · 2001 · 156 citations · 25 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmune Checkpoint InhibitorsNatural Killer Cell BiologyNatural Killer Cell RegulationPharmacodynamics Of ImmunotherapiesAntitumor Immune ActivationImmune Checkpoint Inhibitor TherapyInhibitory Killer Cell Immunoglobulin-like ReceptorsNatural Killer Cell Inhibitory Signaling
Subsets of natural killer (NK) cells are characterized by the expression of inhibitory and/or stimulatory receptors specific for major histocompatibility complex (MHC) class I determinants. In mice, these include the Ly49 family of molecules. One mechanism by which tumor cells may evade NK cell killing is by expressing the appropriate MHC class I and binding inhibitory Ly49 receptors. Therefore, the question of whether blocking the interaction between the Ly49 inhibitory receptors on NK and MHC class I cells on tumor cells augments antitumor activity was investigated. Blockade of Ly49C and I inhibitory receptors using F(ab')(2) fragments of the 5E6 monoclonal antibody (mAb) resulted in increased cytotoxicity against syngeneic tumors and decreased tumor cell growth in vitro. The effect of 5E6 F(ab')(2) was specific for the MHC of the tumor, as the use of F(ab')(2) of the mAb against Ly49G2 failed to increase NK activity. Treatment of leukemia-bearing mice with 5E6 F(ab')(2) fragments or adoptive transfer of NK cells treated ex vivo with the F(ab')(2) resulted in significant increases in survival. These results demonstrate that blockade of NK inhibitory receptors enhances antitumor activity both in vitro and in vivo, suggesting that NK inhibitory receptors can be responsible for diminishing antitumor responses. Therefore, strategies to block inhibitory receptors may be of potential use in increasing the efficacy of immunotherapy. (Blood. 2001;97:3132-3137)
25
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison · Science · 1996 · 3.9K citations
Life Sciences, Immunology, Oncology +17
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Klas Kärre, Hans Ljunggren, Gerald E. Piontek et al. · Nature · 1986 · 2.1K citations
Life Sciences, Immunology, Oncology +12
MHC Class I Deficiency: Susceptibility to Natural Killer (NK) Cells and Impaired NK Activity
Nan‐Shih Liao, Mark Bix, Maarten Zijlstra et al. · Science · 1991 · 479 citations
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
James H. Finke, Arnold H. Zea, Jill Stanley et al. · PubMed · 1993 · 386 citations
Life Sciences, Immunology, Oncology +13
Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo
Helen E. Farrell, Hassan Vally, Donald M. Lynch et al. · Nature · 1997 · 306 citations · Full text